Compare PCOR & EXAS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | PCOR | EXAS |
|---|---|---|
| Founded | 2003 | 1995 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Computer Software: Prepackaged Software | Medical Specialities |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 12.3B | 11.0B |
| IPO Year | 2021 | N/A |
| Metric | PCOR | EXAS |
|---|---|---|
| Price | $77.53 | $101.06 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 18 | 20 |
| Target Price | ★ $83.06 | $76.38 |
| AVG Volume (30 Days) | 1.3M | ★ 10.3M |
| Earning Date | 11-05-2025 | 11-03-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | $1,275,450,000.00 | ★ $3,082,033,000.00 |
| Revenue This Year | $16.35 | $19.40 |
| Revenue Next Year | $12.09 | $13.51 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ 14.94 | 14.47 |
| 52 Week Low | $53.71 | $38.81 |
| 52 Week High | $88.92 | $101.87 |
| Indicator | PCOR | EXAS |
|---|---|---|
| Relative Strength Index (RSI) | 60.44 | 89.74 |
| Support Level | $74.36 | $100.98 |
| Resistance Level | $76.70 | $101.43 |
| Average True Range (ATR) | 2.51 | 2.25 |
| MACD | 0.37 | 0.53 |
| Stochastic Oscillator | 92.58 | 97.74 |
Procore Technologies Inc is a cloud-based construction management software company. It generates revenue through subscriptions for access to its software products. The company's products include Design Coordination, BIM, Field Productivity, Project Financials, Invoice Management, Portfolio Financials, Capital Planning, Accounting Integrations, and Analytics. The software products are hosted on its cloud-based SaaS construction management platform. Subscriptions are sold for a fixed fee and revenue is recognized ratably over the term of the subscription.
Exact Sciences, headquartered in Madison, Wisconsin, provides cancer screening and diagnostic test products in the United States and internationally. Exact's Cologuard screening test is a noninvasive stool-based DNA test for colorectal cancer. The company also competes in the precision oncology market with Oncotype DX, a suite of tissue-based genomic tests for estimating recurrence risk and likelihood of benefit from chemotherapy for breast and colon cancer, and OncoExTra, a liquid-based comprehensive genomic profiling test. It also has a pipeline of blood-based tests for molecular residual disease, colorectal cancer screening, and multicancer screening.